✦ LIBER ✦

Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers

✍ Scribed by Neesha C. Dhani; Urban Emmenegger; Laurie Adams; Jan Jongstra; Ian F. Tannock; Srikala S. Sridhar; Jennifer J. Knox; John R. Day; Jack Groskopf; Anthony M. Joshua

Book ID: 115199488
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 191 KB
Volume: 110
Category: Article
ISSN: 1464-4096
DOI: 10.1111/j.1464-410x.2011.10922.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized phase II study of danusertib

Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure

✍ Hielke J. Meulenbeld; Jean P. Bleuse; Elio M. Vinci; Eric Raymond; Giordano Vita 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 245 KB

A phase 2 study of estramustine, docetax

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer : Results from Cancer and Leukemia Group B Study 90006

✍ Joel Picus; Susan Halabi; W. Kevin Kelly; Nicholas J. Vogelzang; Young E. Whang; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 2 views

209 POSTER An open-label, multicenter, p

209 POSTER An open-label, multicenter, phase 1/2 study of AT-101 in combination with docetaxel and prednisone in men with hormone refractory prostate cancer

✍ G. MacVicar; F.A. Greco; J. Reeves; B. Curti; B. Poiesz; B. Somer; K. Brill; L. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 79 KB

7036 Phase II study with pharmacodynamic

7036 Phase II study with pharmacodynamic evaluation of docetaxelprednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC)

✍ Fontana, A.; Galli, L.; Derosa, L.; Minuti, G.; D'Arcangelo, M.; Bursi, S.; Land 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

The Canadian Uro-Oncology Group multicen

The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone

✍ Fred Saad; Dean Ruether; Scott Ernst; Scott North; Tina Cheng; Paul Perrotte; Pi 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

P114 Safety and efficacy of orteronel (T

P114 Safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Phase 2 results from a phase 1/2 study

✍ Petrylak, D.; Gandhi, J.; Clark, W.R.; Heath, E.I.; Lin, J.; Oh, W.K.; Agus, D.B 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 61 KB